Current Report Filing (8-k)
26 Giugno 2023 - 12:16PM
Edgar (US Regulatory)
0001335105
false
0001335105
2023-06-23
2023-06-23
0001335105
LIXT:CommonStockParValue0.0001PerShareMember
2023-06-23
2023-06-23
0001335105
LIXT:WarrantsToPurchaseCommonStockParValue0.0001PerShareMember
2023-06-23
2023-06-23
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported): June 23, 2023
LIXTE
BIOTECHNOLOGY HOLDINGS, INC.
(Exact
name of registrant as specified in its charter)
delaware |
|
001-39717 |
|
20-2903526 |
(State
or other jurisdiction
of
incorporation) |
|
(Commission
File
Number) |
|
(I.R.S.
Employer
Identification
Number) |
680
East Colorado Boulevard, Suite 180
Pasadena
California 91101
(Address
of principal executive offices)
(631)
830-7092
(Registrant’s
telephone number, including area code)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (See General Instruction A.2. below):
☐ |
Written
communications pursuant to Rule 425 under the Securities Act of 1933 (17 CFR 230.425) |
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(e) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of Each Class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
Common
Stock, par value $0.0001 per share |
|
LIXT |
|
The
NASDAQ Stock Market, LLC |
Warrants
to Purchase Common Stock, par value $0.0001 per share |
|
LIXTW |
|
The
NASDAQ Stock Market, LLC |
On
June 23, 2023, the Company issued a press release announcing that it has received confirmation from The Nasdaq Stock Market, LLC that
it has regained compliance with the Nasdaq minimum bid price requirement.
Item
9.01. | Financial
Statements and Exhibits. |
(d)
There is filed as part of this report the exhibit listed on the accompanying Index to Exhibits, which exhibit is incorporated herein
by reference.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
Date:
June 26, 2023 |
LIXTE
BIOTECHNOLOGY HOLDINGS, INC. |
|
|
|
|
By: |
/s/ JOHN S. KOVACH |
|
|
John
S. Kovach, Chief Executive Officer |
INDEX
TO EXHIBITS
Grafico Azioni Lixte Biotechnology (NASDAQ:LIXT)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Lixte Biotechnology (NASDAQ:LIXT)
Storico
Da Set 2023 a Set 2024